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The effects of several antimicrobial agents are predicted by the ratio of the area under the concentration-time curve (AUC) to the
MIC (AUC/MIC). Peak (Cp) and trough (Ct) concentrations are often measured clinically as surrogates of AUC because actual
computation of AUC from 1 or 2 samples requires sophisticated mathematical methods. Given that the effects of daptomycin are
predicted by AUC/MIC, our objective was to compare simple equation calculated AUC based on Cp and Ct to model integrated
AUC. A standard population pharmacokinetic model was used to simulate 5,000 daptomycin concentration-time profiles after 5
doses of 6 mg/kg of body weight/day (0.5-h infusions). The AUC for the 24-h period was computed by integration and by equa-
tions with 110 Cp-Ct combination pairs. The Cp time points were in 15-min increments between 0.5 h and 3 h and Ct in 15-min
increments within an hour of the end of the dosing interval for each dose. The precision and bias of the calculated AUC relative
to the integrated AUCwere determined to identify Cp-Ct pairs associated with the lowest bias and highest precision. The equa-
tions were further validated using two daptomycin concentration-time data sets from healthy volunteers and critically ill pa-
tients. The precision and bias of calculated AUCwere based primarily on Cp, and use of a daptomycin Cp 1.5 h to 3 h from the
start of infusion was associated with a bias of<10% and an R2 of>0.95. Data from the healthy volunteers and critically ill pa-
tients also demonstrated declining bias with use of Cp>1.5 h from the start of infusion with relatively good precision. Simplified
equations using a daptomycin Cp approximately 2 h from the start of infusion and a Ct within an hour of the end of the dosing
interval should yield precise and unbiased estimates of daptomycin AUC.
The aminoglycosides, vancomycin, and daptomycin are key ex-amples of antimicrobial agents that demonstrate a good cor-
relation between their ratios of area under the concentration-time
curve (AUC) to MIC (AUC/MIC) and effects (1). The systemic
AUC of a drug is dependent on the dose administered and its
systemic clearance (CL). Drug CL is highly variable in certain
populations, such as the critically ill, and is not easily predicted on
an individual level based solely on clinical parameters (2, 3). Se-
lection of a specific dose in a critically ill patient may or may not
achieve the desired AUC for optimal effect (2, 3). Therapeutic
drug monitoring (TDM) has been utilized to overcome this fun-
damental clinical limitation and is used to optimize aminoglyco-
side and vancomycin dosing (4, 5). As an example, initial amin-
oglycoside doses are based onweight, whilemaintenance doses are
based on measured concentrations in serum. This TDM practice
has contributed to the evolution of empirical aminoglycoside
(gentamicin) dosing from 0.5 mg/kg of body weight twice daily to
7 mg/kg once daily for Gram-negative infections over a 40-year
period of clinical use (4).
Similar to this experience, the dosing of daptomycin has
changed over the past 20 years, from 2- to 3-mg/kg divided daily
doses in initial trials to the regulatory approval of a higher single
daily dose of 6 mg/kg for methicillin-resistant Staphylococcus au-
reus (MRSA)-related bloodstream infections (BSI) (6). More re-
cently, experts have suggested that higher daptomycin dosages, 8
to 10mg/kg/day, should be considered to treatMRSABSI (7).Our
group has shown that the use of daptomycin at 6 to 8 mg/kg does
not reliably optimize the pharmacokinetic-pharmacodynamic
(PK-PD) profile of this agent in critically ill patients (8). Use of an
empirical average fixed dose of 750 mg is forecast to achieve com-
parable probability of target attainment (PTA) as 10 mg/kg for
effect but with a lower probability for trough concentrations as-
sociated with toxicity (8). However, a fundamental limitation of
any population-predicted average dose is that it cannot guarantee
with absolute certainty that optimal PK-PD target attainment is
achieved on an individual level.
To date, certain clinical groups have utilized TDM to optimize
the dose of daptomycin for selected cases (9–12). As with any
nascent approach, a clearly defined system to measure and inter-
pret daptomycin concentrations remains to be elucidated. Histor-
ically, clinicians havemeasured peak (Cp) and/or trough (Ct) con-
centrations of drugs and correlated these point estimates to safety
or efficacy related outcomes. Although clinical interpretation of a
single point measurement is simple, it is unlikely to accurately
reflect the true exposure-response relationship. We recognize the
AUC/MIC as the PK-PD index predictive of daptomycin effect, so
it would be rational to transform measured daptomycin concen-
trations into AUC values on an individual basis. The most accu-
rate approach to computation of AUCwith a single measurement
of concentration in serum includes the use of sophisticated max-
imum a priori probability (MAP) Bayesian methods (13). Alter-
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natively, a simple hand-calculated approach can be used to accu-
rately quantify the AUC using two serum sample measurements
(peak and trough) for intravenously administered antimicrobials
(4). This simple mathematical approach accurately predicts ami-
noglycoside AUC (4). As the shape of the aminoglycoside concen-
tration-time profile is similar to that of daptomycin, an analogous
approach to daptomycin AUC calculation is plausible.
Our study objective is to define a simple clinically implement-
able “bedside” approach to aid clinicians who desire to transform
measured daptomycin concentrations to AUC values. Measure-
ment and translation of daptomycin concentration-time datamay
also aid clinical scientists who seek to best define and validate the
clinical exposure-response relationships. We show using model-
ing and simulation that daptomycin AUC can be computed accu-
rately and simply with two concentrationmeasurements based on
actual data from healthy and critically ill populations.
MATERIALS AND METHODS
Modeling and simulation approach. This investigation involved a three-
step approach to define a simplemethod to the computation of daptomy-
cin AUC values. The first step included use of a well-described daptomy-
cin population PK model to generate simulated concentration-time
profiles. Concentration-time pairs (peak and trough) from each simu-
lated profile were used to compute AUC using a simple mathematical
formula and compared to the model integrated AUC value. The model
integrated AUC value served as the gold standard. The time point pairs
associated with the lowest bias were identified. The second step was to
validate this approach using data from a cohort of healthy volunteers
based on concentration-time data after administration of a single dapto-
mycin dose. The third step was to also validate this approach using data
from critically ill patients with concentration-time data after single and
multiple doses. Details for each methodological step are provided as fol-
lows.
Step 1: daptomycin population pharmacokinetic model simula-
tions. A standard open 2-compartment population pharmacokinetic
model with zero-order input, first-order output, and transfer between
compartments was used to generate simulated daptomycin concentra-
tion-time profiles (14). The pharmacokinetic parameter estimates for
clearance (CL), central compartment volume of distribution (Vc), and
intercompartmental transfer rate constants (kcp and kpc) were obtained
from a previous study. The mean (standard deviation) values for the PK
parameters were as follows: CL, 0.957 (0.461) liter/h;Vc, 6.56 (3.10) liters;
kcp, 1.67 (3.04) h
1; and kpc, 1.34 (3.40) h
1. These PK parameters were
defined based on data from 108 adult patients who participated in the
phase 3 bacteremia and endocarditis study of daptomycin at 6 mg/kg
every 24 h (15). A 5,000-subject Monte Carlo simulation was imple-
mented using ADAPT 5 with selection of log normal distributions for
these PK parameters (14). The simulation included five daptomycin doses
of 6 mg/kg infused over 0.5 h every 24 h based on a mean (standard
deviation) body weight of 82.2 (18.6) kg tomimic the original population
PK data set (15).
It is difficult to measure the peak concentration exactly at the end of
infusion in the clinical setting and the trough concentration exactly prior
to the next dose. Due to this clinical limitation, 11 time points in 15-min
increments were captured to represent the “peak” concentration (Cp)
between the end of infusion and 2.5 h postinfusion after the first (0 h) and
fifth (96 h) doses: 0.5 h, 0.75 h, 1 h, 1.25 h, 1.5 h, 1.75 h, 2.0 h, 2.25 h, 2.5
h, 2.75 h, and 3.0 h and 96.5 h, 96.75 h, 97 h, 97.25 h, 97.5 h, 97.75 h, 98 h,
98.25 h, 98.5 h, 98.75 h, and 99 h from the start of infusion. The trough
concentrations (Ct) were represented by 5 time points in 15-min incre-
ments within 1 h of the end of the dosing interval: 23 h, 23.25 h, 23.5 h,
23.75 h, and 24 h (first dose) and 119 h, 119.25 h, 119.5 h, 119.75 h, and
120 h (fifth dose). Evaluation of these time points permitted generation of
55 possible peak-trough combinations after the first and fifth doses in
order to test effects of the sampling time point on hand-calculated AUC
estimates. These peak-trough combinations were expected to reflect the
potential clinical approach that may be used to measure daptomycin, i.e.,
FIG 1 Population model simulated concentration-time curve of daptomycin
curve (6mg/kg every 24 h for 5 doses), with shaded regions illustrating the area
under the curve after the first and fifth doses with the area of a triangle (first
dose, 0 h) and area of a trapezoid (fifth dose, 96 h).
FIG 2 Percent error (A) and coefficient of determination (B) for the AUC24 calculation by dose number and time from start of daptomycin infusion compared
to the integrated AUC24 value.
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peakmeasurement a few hours after the end of infusion and trough before
the next dose. We also sought to demonstrate the effects of sample mea-
surement after a single dose and multiple doses on AUC calculation. A
differential equation was embedded within the model simulation to gen-
erate integrated AUC values for the sampling time points that permitted
estimation of AUC for the 24-h period (AUC24) after the first and fifth
doses. The integrated AUC24 after the specific dose served as the reference
standard.
Calculation of area under the curve. The equations to compute
AUC24 from two samples are based in part on an original approach pro-
posed by Begg et al. for aminoglycosides (16) and modified by Pai and
Rodvold (4). We used 55 peak-trough concentration (Ct, where t is time
point in hours) pairs after the first and fifth doses as outlined above, e.g.,
C0.5-C23, C0.5-C23.25, and C0.5-C23.5, to compute the elimination rate con-
stant (kel) based on the Sawchuk-Zaske method (17).
kel
LnCpCt 
t
(1)
where Cp is the peak concentration, Ct is the trough concentration, and t
is the difference in time between these two concentrations. TheAUC24 can
be expressed as the summation of the area of a triangle (after the first dose)
or a trapezoid (multiple doses) plus the integral of the concentration-time
curve (Fig. 1). The equations for these computations are provided as fol-
lows: for single-dose AUC24 (first dose as an example),
AUC0-24 0.5 · t  · Cmax t
infinity
Cmax · e
kel · (t) dt
 24
infinity
Cmin · e
kel · (t) dt (2)
Equation 2 can be simplified to
AUC24
t  · Cmax
2

Cmax Cmin
kel
(3)
For multiple-dose AUC24 (fifth dose as an example),
AUC96-120 0.5 · t  · (Cmax Cmin) t
infinity
Cmax · e
kel · (t) dt
 120
infinity
Cmin · e
kel · (t) dt (4)
Equation 4 can be simplified to
AUC24
t · Cmax Cmin
2

Cmax Cmin
kel
(5)
where t= is the time of infusion (h), Cmax is the peak concentration at the
end of infusion, and Cmin is the trough concentration at the end of the
dosing interval. Given that peak concentrations may be measured up to
2.5 h after the end of infusion in this simulation, concentrationsmeasured
between 0.75 h and 3 h were extrapolated to the end of infusion using the
Sawchuk-Zaskemethod. Similarly, trough concentrations sampled before
the end of the dosing interval were extrapolated to the expected value at
the end of the dosing interval. The percent error for computed AUC24
compared to integrated AUC24 was calculated for each of the 55 concen-
tration-pairs for the first and fifth doses. Ordinary least-squares regres-
sion was also used to define the coefficient of determination for the com-
puted AUC24 compared to integrated AUC24 values. The partial AUC
between 0.5 h (end of infusion) and 2 h from the start of infusion was also
calculated and defined as the distribution-phase AUC. The purpose of this
calculation was to define the potential AUC not captured by our mono-
exponential decline assumption relative to the biexponential decline ex-
pectation of a 2-compartment system.
Step 2: validation using healthy volunteer data. The raw concentra-
tion-time data from a previous study evaluating the single-dose plasma
PK of daptomycin at 4 mg/kg in 7 normal-weight and 7 morbidly obese
healthy female subjects were used (18). The AUC24 (reference standard)
was calculated by integration using the aforementioned 2-compartment
model and individual maximum a priori Bayesian probability procedure
in ADAPT 5 (14). The AUC24 was also calculated using equation 3 above
for a single dose. For this AUC24 (calculated by equation), concentrations
collected at the end of infusion (0.5 h) and at 1 h, 1.5 h, 2 h, and 4 h served
as the peak measurement, while the measurement at 24 h served as the
trough. The percent error for calculated AUC24 compared to integrated
(reference standard) AUC24 was computed for each of the 5 peak-trough
concentration pairs. Ordinary least-squares regression was used to com-
pare the calculatedAUC24 to the reference standardAUC24 values for each
pair.
Validation using data from critically ill patients.The raw concentra-
tion-time data from a previous study evaluating themultiple-dose plasma
PK of daptomycin at 6 to 8mg/kg in 50 patients were used (8). The AUC24
(reference standard) was calculated using the aforementioned maximum
a priori Bayesian probability procedure in ADAPT 5 by integration (14).
The AUC24 was also calculated using equation 3 above for a single dose
and using equation 5 for doses 2 to 5. For this AUC24 calculation, concen-
trations collected at approximately 0.5 h, 1 h, 2 h, and 4 h served as the
peak measurement, while the measurement at 24 h served as the trough
after the first dose. For doses 2 to 5, a peak concentration was measured
approximately 1 h from the start of infusion and trough just prior to the
dose. The percent error for calculated AUC24 compared to integrated
AUC24 (reference standard) was determined for each of the peak-trough
concentration pairs. Ordinary least-squares regression was used to com-
pare the calculated AUC24 to the model integrated AUC24 values for each
pair. Statistical analyses were implemented using STATA SE version 13
(StataCorp, College Station, TX).
RESULTS
Daptomycin population pharmacokinetic model simulations.
The mean concentration-time profile generated by the simula-
tions is illustrated in Fig. 1. The mean (standard deviation) values
for the simulated PKparameters were as follows: CL, 0.959 (0.451)
liter/h; Vc, 6.47 (3.03) liters; kcp, 1.67 (3.11) h
1; and kpc, 1.34
(3.22) h1. These values matched the population’s prior esti-
mates. The mean (standard deviation) weight simulated was 82.0
(18.4) kg, which led to a simulated (6 mg/kg) daptomycin dosage
of 492 (110) mg/day. The mean (standard deviation) concentra-
tions at the end of infusion after the first and fifth doses were 69.4
(39.1) mg/liter and 79.6 (39.5) mg/liter, respectively. The mean
(standard deviation) concentrations at the end of the dosing in-
terval were 5.81 (4.79) mg/liter and 10.9 (9.67) mg/liter after the
first and fifth doses, respectively. The mean (standard deviation)
AUC24 for the simulated doseswere 373 (233)mg · h/liter (dose 1),
462 (276) mg · h/liter (dose 2), 504 (294) mg · h/liter (dose 3), 530
(304)mg · h/liter (dose 4), and 547 (310)mg · h/liter (dose 5). The
geometric mean AUC24 ratios (90% confidence intervals) of se-
quential doses were 1.282 (1.278, 1.288) (dose 2/dose 1), 1.113
(1.110, 1.115) (dose 3/dose 2), 1.062 (1.061, 1.064) (dose 4/dose
3), 1.040 (1.039, 1.041) (dose 5/dose 4), and 1.577 (1.563, 1.592)
(dose 5/dose 1). The mean (95% confidence interval) distribu-
tion-phase AUC represented 5.07% (4.91%, 5.23%) and 3.46%
(3.32%, 3.60%) of the AUC24 after dose 1 and dose 5, respectively.
Calculation of area under the curve.The bias and precision of
the AUC24 were primarily influenced by the peak concentration
time point and not by the trough concentration time point. Figure
2A illustrates a clear reduction in the mean percent error from 50
to 90% to approximately10% between 0.5 h and 3 h, with con-
vergence of the error to near 0% between 2 h and 2.25 h. Use of a
simulated peak concentration-time point between 1.5 h and 3 h
was associated with approximately a10% bias in the estimate of
AUC24 after doses 1 and 5using the stated equations. Similarly, the
precision of calculated AUC24 increased with use of a peak con-
Pai et al.
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centration time point above 0.5 h with convergence to an R2 of
0.95 between 1.5 h and 1.75 h.
Validation using data from healthy volunteers. As suggested
by the populationmodel simulations, use of a peak concentration-
time point at the end of infusion was associated with the greatest
positive bias in the calculated AUC24. Table 1 includes the mean
(95% confidence interval) AUC24, percent error, and precision
(R2) for each of the concentration-time pairs that were tested. The
R2 was highest with use of the 1.5-h peak concentration-time
point, which was also associated with an unbiased estimate of the
AUC24 value. Use of the 4-h time point as a peak value was asso-
ciated with underestimation of AUC24 by9.87%.
Validation using data from critically ill patients.Uses of con-
centrations after 0.5 h as the peak measurement were associated
with declining bias. The mean (95% confidence interval) AUC24,
percent error, andR2 for each of the concentration-time pairs that
were tested are provided in Table 2. As shown, use of the 0.5-h
time point after the first dose was associated with a mean (95%
confidence interval) error of 46.2% (30.1%, 62.3%) and was un-
biased with the use of the 2-h (lowestmean bias) or 4-h time point
as the peak measurement. Use of the 1-h time point as the peak
was associated with a mean (95% confidence interval) error of
12.1% (1.71%, 22.6%). As stated in Materials and Methods, only
single time points approximately 1 h from the start of infusion
were available after doses 2 to 5. Fewer observations were available
for doses 2 to 5 than for dose 1. Although good precision was
observed (R2 0.7) for calculated AUC24 values, use of the single
peak concentrationmeasurement was associated with amean bias
of 6.14% to 37.2%. Linear regression of all calculated AUC24 val-
ues using the data from 1 h from the start of infusion only dem-
onstrated good overall precision (R2 0.806). However, as illus-
trated in Fig. 3, use of the data from 1 h after start of infusion from
the single and multiple doses was associated with significant pos-
itive bias.
DISCUSSION
Selection of the optimal individual antimicrobial dosage regimen
is problematic in clinical practice due to interindividual PK vari-
ability. Population pharmacokinetic analysis has emerged as a sci-
ence to identify sources of this interindividual variability andmit-
igate them through the design of regimens that increase the PTA
(13). Body weight and kidney function estimates have often been
identified as sources of this interindividual variability and have
been used to aid antimicrobial dosing. Unfortunately, critically ill
patients experience dynamic shifts in physiologic function that
can reduce the predictability of interindividual antimicrobial PK
(2, 3). As a consequence, TDM is applied in clinical practice to
overcome this problem. Unfortunately, the application of TDM is
hindered by the lack of availability of assays to expedite analysis
and technical knowhow on the interpretation of these data. How-
ever, the delivery of optimal antimicrobial pharmacotherapy is
predicated on overcoming these fundamental challenges.
Our group has demonstrated through the use of TDM that the
current daptomycin dosing recommendations on body weight
and kidney function are no better than fixed dosing at achieving
the AUC target for effect in critically ill patients (8). Specifically,
use of 750 mg/day in patients with sepsis and 500 mg/day in pa-
tients not in sepsis is expected to achieve PTA comparable to those
TABLE 1 Comparison of bias and precision of bedside models compared to integration computed AUC24 values based on single-dose data from
healthy volunteersa
Model Time points AUC24 (mg · h/liter), mean (95% CI) Percent error, mean (95% CI) R
2
Ref All 463 (371, 555) Ref Ref
1 0.5 h, 24 h 499 (393, 606) 13.0 (1.47, 24.0) 0.874
2 1 h, 24 h 476 (396, 555) 3.03 (7.54, 13.6) 0.780
3 1.5 h, 24 h 424 (358, 490) 5.61 (13.7, 2.47) 0.888
4 2 h, 24 h 398 (333, 463) 11.4 (19.0,3.74) 0.828
5 4 h, 24 h 373 (304, 442) 17.2 (24.5,9.87) 0.858
a Ref, referent; CI, confidence interval.
TABLE 2 Comparison of bias and precision of bedside models compared to integration computed AUC24 values based on single- and multiple-dose
daptomycin data from critically ill patientsa
Dose Model No. of observations Time points AUC24 (mg · h/liter), mean (95% CI) Percent error, mean (95% CI) R
2
1 0 50 Ref 488 (427, 549) Ref Ref
1 1 50 0.5 h, 24 h 696 (593, 799) 46.2 (30.1, 62.3) 0.619
1 2 50 1 h, 24 h 535 (468, 602) 12.1 (1.71, 22.6) 0.725
1 3 50 2 h, 24 h 493 (431, 555) 3.67 (7.41, 14.8) 0.689
1 4 49 4 h, 24 h 453 (392, 513) 4.87 (14.7, 4.95) 0.712
2 0 36 Ref 691 (619, 764) Ref Ref
2 1 36 25 h, 48 h 700 (603, 797) 6.14 (9.07, 21.35) 0.854
3 0 26 Ref 723 (642, 805 Ref Ref
3 1 26 49 h, 72 h 859 (667, 1,051) 31.8 (13.7, 50.0) 0.868
4 0 21 Ref 716 (621, 812) Ref Ref
4 1 21 73 h, 96 h 746 (555, 938) 19.3 (3.60, 35.0) 0.870
5 0 25 Ref 717 (610, 824) Ref Ref
5 1 25 97 h, 120 hb 834 (667, 1,000) 37.2 (11.7, 62.7) 0.742
a Ref, referent; CI, confidence interval.
b Value for 120 h defined by superposition of the value for 96 h.
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of dosages of 8 to 10 mg/kg/day but with a lower probability of
toxicity (8). An important caveat of these prior findings is that
they should be validated by other clinical groups to increase gen-
eralizability. As stated, major limitations to validation of this ap-
proach by other groups are accessibility to TDM and the technical
knowhow on the execution ofMAP-Bayesian analyses.We sought
to define a simple clinically implementable “bedside” approach to
aid clinicians who desire to transformmeasured daptomycin con-
centrations to AUC values and perhaps aid in these validations.
Weusedmodeling and simulationwith a standard daptomycin
PKmodel and parameters defined through anMRSA BSI study to
demonstrate that collection of two samples can permit unbiased
estimation of daptomycin AUC24. Collection of the peak sample
between 2 h and 2.25 h was associated with almost no bias. For
more practical consideration, collection of a peak sample 1.5 h to
3 h from the start of the daptomycin infusion and trough within
an hour of the end of the dosing interval was associated with a bias
of nomore than10%. As illustrated in Fig. 1, the concentration-
time profile for the 2-compartment model declines rapidly after
the end of infusion and transitions from the alpha-phase (distri-
bution) to the beta-phase (elimination) around 1.5 to 3 h from the
start of infusion. The AUC of the alpha-phase potentially not cap-
tured by our equation-based assumptions represented a mean of
5.07% of the AUC24. Hence, our observations of lowmean per-
cent error in the AUC24 and high precision (0.95) with selection
of time points in this range are consistent with this expected pro-
file.
Validation of this approach was undertaken using data from
our prior studies with healthy volunteers and critically ill patients
(8, 18). Consistent with our population model approach above,
we observed a trend for positive bias and negative bias around the
time point of 1.5 h as the peak sample point. A similar observation
was noted around the 2-h peak sample pointwith the data set from
critically ill patients. The level of precision was lower with these
validation data sets due to the lower number of observations and
limited sampling time points relative to the simulation data set.
Despite this limitation, the consistent trend across these three data
sets speaks to the potential generalizability of equations 3 and 5
defined in this investigation. We did not conduct a prospective
validation of these equations, so this limitation affects generaliz-
ability. Evaluation of this equation-based AUC calculation ap-
proach by other groups in other patient populations is necessary
to overcome this limitation.
Our demonstration of a clinically feasible approach to com-
pute daptomycin AUC24 after single and multiples doses creates
an opportunity to individually optimize the dose of daptomycin.
Specifically, computation of the AUC24 value based on the admin-
istered dose can be used to calculate a new dose by a proportionate
method, i.e., new dose target AUC24 (current dose/calculated
AUC24). Although a target daptomycin AUC24 value is not well
established to empirically treatMRSA-related BSI, it is expected to
be between 579 and 753 mg · h/liter and should be selected based
on the clinical judgment of the prescriber (19). Alternatively, clin-
ical scientists who seek to identify the optimal daptomycin target
AUC24 or AUC24/MIC (once the pathogen is identified and MIC
defined) could use this approach to aid in such investigation. It is,
however, disingenuous to simply accept that 8- to 10-mg/kg/day
dosages of daptomycin should be used in patients without simul-
taneously accepting that the purpose of this higher dose is to reli-
ably increase the AUC24 to a higher threshold value than with
standard doses (7). Identification of daptomycin AUC24 target
values for different MRSA-related infections and patient popula-
tions will contribute to improve dosing strategies, as has been the
case for aminoglycosides and vancomycin (4, 5).
Our suggested approach of two sample measurements is com-
parable to the practice applied to the dosing of aminoglycosides.
As should be expected, use of sparse sample measurements and a
MAP-Bayesian approach will yield the best results (13). In the
absence of software or the technical knowhow on the execution of
this approach, our simpler approaches may be feasible. Although
limited availability of clinical assays to measure daptomycin con-
centrations hinders the application of this approach, it may be
applicable to other agents. Novel techniques to simultaneously
measure vancomycin, telavancin, daptomycin, and colistin have
been developed that may become routine in some institutions
(20). Evaluation of our approach should be undertakenwith these
agents, as their effects are also predicted by their AUC (1). Fur-
thermore, novel techniques such as dried plasma spot sample col-
lections have recently been validated for the assay of daptomycin
(21). Improved sample collection and analysis techniques by cen-
tralized reference laboratories, for example, could extend TDM to
institutions that do not routinely offer this service (22). As should
be predicted, the AUC values computed by these methods will
vary based on the exact sample time point measurements and
analytical approaches. Although one would expect the bias and
precision of these AUC24 estimates to fall within the range identi-
fied through our evaluation, empirical confirmation of this expec-
tation is needed. Despite these limitations, clinical translation of
the principles outlined in this work will serve as a key step forward
for physicians to individualizing the dose of daptomycin and im-
proving clinical outcomes.
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